Benefits of Combining Cervical Cancer Screening with Human Papillomavirus Testing and Cytology

DOI Web Site Web Site 14 References

Bibliographic Information

Other Title
  • 子宮頸がん検診におけるHPV併用検診の有用性
  • 子宮頸がん検診におけるHPV併用検診の有用性 : 5年間の由利本荘地区におけるHPV併用検診の結果から
  • シキュウケイガン ケンシン ニ オケル HPV ヘイヨウ ケンシン ノ ユウヨウセイ : 5ネンカン ノ ユリ ホンジョウ チク ニ オケル HPV ヘイヨウ ケンシン ノ ケッカ カラ
  • 5年間の由利本荘地区におけるHPV併用検診の結果から

Search this article

Abstract

This study sought to demonstrate the benefits of conducting cervical cytology and human papillomavirus (HPV) testing in our cervical cancer screening program and was conducted between April 2012 and March 2017 in the Yuri-Honjo district of Akita Prefecture. A total of 3581 women aged 20-49 years underwent this combined screening for 5 years. Of these, 10.3% (369/3581) tested positive for HPV, and 433 women were initially diagnosed as positive for atypical squamous cells of undetermined significance and/or positive for HPV. Of those, 342 women (79.0%) underwent cervical biopsy, among whom 62 (18.1%) were diagnosed as positive for cervical intraepithelial neoplasia (CIN)2+. Of 204 women who were positive for HPV but showed no abnormalities in cytology, 24 women (11.8%) were positive for CIN2+ and 6 women were positive for CIN3+. Conventional cytology (Pap test) detected only 0.58% of the examinees positive for CIN2+ in Akita Prefecture, whereas our combined screening involving a Pap test and HPV testing detected 1.73% of the examinees (P<0.0001). We recommend HPV testing be used in combination with the Pap test to improve cervical cancer screening and accurately identify CIN2/3 disease.

Journal

References(14)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top